FDA Advisory Committees: Message to Pharmaceutical Industry and Academia

> Michael Proschan NIAID

Disclaimer

- This is a bait and switch talk
- I don't really have general messages to the pharmaceutical industry and academia
- My comments concern participation as an FDA Advisory Committee panel member or as a presenter to an FDA Advisory Committee

Introduction

- FDA Advisory Committees are outside experts without major conflicts of interest
 - MDs with expertise in specialty under study
 - Statisticians & epidemiologists
 - Other experts as needed
 - Patient/Consumer Representative
 - Industry representative (non-voting)

Introduction

- FDA asks specific questions like:
 - Do you have significant safety concerns with respect to liver toxicity with Product X?
 - Has the sponsor demonstrated efficacy of product X with respect to CHD?
- Committee discusses issues, votes on questions & recommendations to FDA
- FDA makes ultimate decision on approval

Introduction

- Typical order of meetings
 - Sponsor presents
 - Committee asks "clarifying" questions
 - FDA presents
 - Committee asks "clarifying" questions
 - Public Hearing portion
 - Advisory Committee discussion/deliberation
 - Advisory Committee votes & explains vote

Interpretations, not Datasets

- Before meeting, you get briefing documents—FDA's and sponsor's interpretations of data, not datasets
 - Good: not as much work
 - Bad: you can't do your own analyses
- Given that you get only 2 interpretations, want to quickly find where they disagree
 I read FDA briefing document first
 - If FDA has no issues, easy decision

They Don't Give You The Easy Ones

- Very rarely, decisions are easy
 - Sometimes the FDA is required to have FDA Advisory Committee meetings, even if they agree with sponsor (e.g., when there is a new molecular entity)
- Usually the FDA and Sponsor disagree about some things
- You usually don't get the easy ones
 If they were easy, they wouldn't need you!

Analogous to Criminal Trial

- Advisory Committees have commonalities with criminal trials
 - Sponsor is like prosecutor: must prove case beyond reasonable doubt
 - FDA is like defense: makes sponsor prove their case
 - Advisory Committee like jury
 - Sometimes 1 or 2 members are very influential
 - Difference from jury: experts, not peers

Analogous to Criminal Trial

- Each side has its own experts
- Each side presents case separately
 - Evidence can seem overwhelming after one side, but then change when other side presents
- Discovery process: each side sees other side's evidence before trial
- Good strategic decision to present your side's weaknesses before other side does
 - Never want to give impression of hiding something

Analogous to Criminal Trial

- One important difference from criminal trial: jury (Advisory Committee) sees evidence in advance
 - Voluminous materials sent out weeks in advance (though "jury" doesn't always read them)
- Still, sometimes things come up and you have to think fast
- Example: LOTS trial of Pompe disease

- 10/21/2008 Endocrinologic and Metabolic Drugs Advisory Committee meeting on Pompe disease
 - Very rare, debilitating neuromuscular disease
 - Infant onset, juvenile onset, adult onset
 - Infant onset is most deadly, adult onset is still bad
 - Patients often progress to wheelchair dependence, ventilator, and death


- Genzyme conducted Late Onset Treatment Study (LOTS)
- 90 patients with late onset Pompe disease
- Primary outcome: 6 minute walk test
- 2:1 allocation to drug/placebo using *minimization*
 - Try to balance on site, BL 6 minute walk (≤300m, >300m), and forced vital capacity (≤55% pred., >55% pred.)

- The FDA is skeptical about minimization, so they require companies to use a rerandomization test
 - Compute observed test statistic T_{obs}
 - Fix data, regenerate treatment labels using allocation algorithm, compute T, and repeat thousands of times
 - Compute p-value by seeing where T_{obs} is in this *re-randomization distribution*

- Proponents of minimization argue that you can do a re-randomization test, but it is unnecessary because you get about same answer as t-test
- The statistician argued that rerandomization test doesn't work in LOTS

Problem with Application of Rerandomization Test in Analysis of 6MWT

Distribution of 6MWT ANCOVA test statistics



ANCOVA p=.035

Re-randomization p=.06

- Big problem: mean of re-randomization distribution is NOT 0 because of 2:1 allocation
 - It is 0 for standard randomization methods
- Nonzero mean causes loss of efficiency of re-randomization test: no longer close to ttest even for very large sample sizes
- Problem is that minimization severely limits amount of randomization

- For more details on LOTS trial, see Van der Ploeg et al (2010) NEJM 362, 1396-1406
- For more details about statistical problems minimization caused, see:


Proschan, M., Brittain, E., and Kammerman, L. (2011). Minimize the use of minimization with unequal allocation. *Biometrics* **67**, 1135-1141

Experts and Presentation

- Most important job for expert is to communicate effectively to statisticians and non-statisticians
 - Try to explain, not to impress
 - Give analogies
 - A p-value of .03 is like rolling a pair of sixes
 - Interaction:
 - 2 kids in the back seat
 - Will better team still win in soccer if it rains

Experts and Presentation


- Use graphs whenever possible
- Graphs are very helpful for illustrating statistical concepts
- E.g., for regression to the mean:




End of Study

Baseline eGFR<60

(kidney measure)




Month 1 eGFR<60



Experts and Presentation


- What to avoid in graphs:
 - Overcrowding with labels
 - Needless 3-dimensionality
 - Gratuitous use of colors
 - Think carefully about choice of colors (use placid blue for your drug, alarming red for placebo)
 - Scaling games





Prevention of rejection of heart in heart transplant

Survival* Through 24 months Study XXX—Kaplan-Meier Analysis



95% Cls and number of patients at risk shown at 3, 6, 12, and 24 months. *Freedom from graft loss/death/lost to follow-up through 24 months.


Experts and Presentation

- Sometimes the experts are very well known (e.g., L.J. Wei, Richard Peto, Donald Rubin, etc.)
- If you are on AC, the FDA wants YOUR opinion; don't be swept away if expert is famous
- No-no: "We have some world renowned experts here—let's ask them"

- 4/29/2010 FDA Anti-Infective Drugs Advisory Committee meeting:
- In remote locations, malaria sometimes kills people before they can reach the hospital
- Artesunate suppositories intended to reduce parasites & keep person alive until they reach a hospital

- Trial 13 compared artesunate suppository to placebo suppository
 - Children under 6 got 100mg dose
 - Adults & children over 6 got 400mg
- Analysis plan called for separate analyses in the two age subgroups
- Results suggested benefit for young children, harm for older children
- Is this real?

Figure 4. Kaplan-Meier Survival Curves for Time to Death, All Randomized Patients



Younger ChildrenOlder Children/AdultsBangladesh/ChittagongBangladesh/Chittagong

ART	PLA	ART	PLA
14/1022	31/988	31/2009	14/2009
(1.4%)	(3.1%)	(1.5%)	(0.7%)
RR=0.43 (0.2,0.8)		RR=2.2 (1.1,4.2)	
p=.007		p=.01	

Modified ITT Population

- Richard Peto argued conflicting results are due to play of chance
- As with many other AC meetings, I had not made up my mind in advance
- It is okay to have doubts
 - The FDA values your thinking
 - Talk! Don't be afraid your questions are dumb
 - People with no doubts may be less convincing

- Expert was Richard Peto:
 - Famous & brilliant
 - Excellent at explaining things to statisticians and non-statisticians
- I began thinking:
 - I can't disagree with Peto!
 - He's probably right—he usually is
 - Cholesterol lowering and suicide/victim of homicide

- In the end, you have to go with your gut
- You are there to give an independent opinion
- If you are not convinced, it doesn't matter how famous the expert is
- We decided that differences between younger and older children were probably not the play of chance

Not JUST A Statistician

- Statisticians also need to use nonstatistical judgment as well, e.g. :
- 12/14-15/2006 Anti-Infective Drugs AC and Drug Safety and Risk Mangement AC
 - Ketek for 3 different conditions:
 - Community acquired pneumonia (CAP)
 - Acute exacerbations of chronic bronchitis (AECB)
 - Acute bacterial sinusitis (ABS)

Not JUST A Statistician

- Rare, but troubling side effect-diplopia
 Concern about driving
- I thought it should be approve for more serious condition (CAP) because less likely to drive
 - Patients with CAP are less likely to feel well enough to drive

Respect the Public Hearing: You Might Learn Something

- Advisory Committee members sometimes ignore public speakers
 - They talk, read e-mails, etc.
- This is bad on several levels
 - Disrespectful to people who may already be afraid of public speaking
 - It gives an impression that you don't care about patients suffering from the disease
 - You might learn something useful
 - Better understanding of disease and patients

Respect the Public Hearing: You Might Learn Something

- I have been on several ACs involving weight loss drugs
- Some have had troubling side effects, especially in large doses
- One public speaker talked about how desperate extremely obese people are:
 – Likely to take more than prescribed dose
- Had a big effect on my deliberations

May Not Want to Participate if You Have the Disease

- I have kidney disease (IGA nephropathy)
- On 10/16/2007 I was a consultant on the Cardiovascular and Renal Drugs AC meeting
 - Phosphate binders for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD)
- Sponsor presented slide with these bullet points:

May Not Want to Participate if You Have the Disease

- 11.3 million Americans have CKD, and excessively high mortality risk due to cardiovascular disease
- Most patients with CKD die before reaching dialysis
- Risk of death is extreme in end stage kidney failure
- 30 year old person with CKD Stage 5 on dialysis has risk of death equivalent to 90 year old

Summary

- FDA AC participation is great way to help the FDA and a great learning experience

 Exciting learning experience as a spectator too
- Talk! The FDA wants to hear your reasoning

 Try to explain, not to impress
- Use both statistical reasoning and common sense
- Don't ignore the public speakers
- Avoid ACs for diseases you have!